Sadamu Homma
Overview
Explore the profile of Sadamu Homma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sawada R, Arai Y, Sagawa Y, Nagata Y, Nishimura T, Noguchi M, et al.
Oncol Rep
. 2019 Sep;
42(5):2057-2064.
PMID: 31545443
The interaction between tumor necrosis factor receptor superfamily, member 4 (OX40) on T cells and the OX40 ligand (OX40L) on antigen‑presenting cells (APCs) is a pivotal step for T‑cell activation...
2.
Shimamoto N, Imazu H, Homma S, Sumiyama K
Endosc Ultrasound
. 2019 Feb;
8(1):69-71.
PMID: 30777942
No abstract available.
3.
Okui N, Kamata Y, Sagawa Y, Kuhara A, Hayashi K, Uwagawa T, et al.
Pancreatology
. 2018 Nov;
19(1):88-96.
PMID: 30416041
Background/objectives: Pancreatic cancer consists of various subpopulations of cells, some of which have aggressive proliferative properties. The molecules responsible for the aggressive proliferation of pancreatic cancer may become molecular targets...
4.
Okuma Y, Hishima T, Kashima J, Homma S
Cancer Immunol Immunother
. 2018 Aug;
67(9):1477-1479.
PMID: 30084040
The graphs are incorrectly identified in Fig. 3i, s and should be replaced with the following.
5.
Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, et al.
Clin Lung Cancer
. 2018 Jun;
19(5):410-417.e1.
PMID: 29859759
Background: Biomarkers for predicting the effect of anti-programmed cell death 1 (PD-1) monoclonal antibody against non-small-cell lung cancer (NSCLC) are urgently required. Although it is known that the blood levels...
6.
Okuma Y, Kashima J, Watanabe K, Homma S
J Cancer Res Clin Oncol
. 2018 Jun;
144(8):1601-1611.
PMID: 29858682
Purpose: Metastasis of non-small cell lung cancer (NSCLC), indicating hematogenous dissemination, is more frequent in patients harboring epidermal growth factor receptor (EGFR) mutations, who respond dramatically to EGFR-tyrosine kinase inhibitors...
7.
Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, et al.
Cancer Immunol Res
. 2018 Jan;
6(3):320-331.
PMID: 29358173
We investigated the efficacy of a Wilms' tumor gene 1 (WT1) vaccine combined with gemcitabine (GEMWT1) and compared it with gemcitabine (GEM) monotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) in...
8.
Okuma Y, Hishima T, Kashima J, Homma S
Cancer Immunol Immunother
. 2017 Dec;
67(3):495-505.
PMID: 29243049
Background: The status of antitumor immunity represented by the expression of programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) and immune cell (IC) infiltration is unknown in HIV-infected patients with...
9.
Ito M, Hayashi K, Minamisawa T, Homma S, Koido S, Shiba K
PLoS One
. 2017 Dec;
12(11):e0188934.
PMID: 29190754
Adjuvants are indispensable for achieving a sufficient immune response from vaccinations. From a functional viewpoint, adjuvants are classified into two categories: "physical adjuvants" increase the efficacy of antigen presentation by...
10.
Homma S, Hayashi K, Yoshida K, Sagawa Y, Kamata Y, Ito M
Int Immunopharmacol
. 2017 Nov;
54:39-45.
PMID: 29100036
Programmed cell death ligand-1 (PD-L1) plays a pivotal role in the suppression of antitumour immunity by binding to programmed cell death-1 (PD-1) on tumouricidal cytotoxic T lymphocytes (CTLs), rendering them...